© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company’s listing at the NYSE in New York
BRUSSELS (Reuters) – EU antitrust regulators opened on Wednesday a full-scale investigation into Johnson & Johnson’s (N:) buy of Takeda Pharmaceutical Co’s (T:) surgical patch product TachoSil, saying the deal may hurt competition and innovation.
The European Commission set an Aug. 10 deadline for its decision on the deal.
Japan’s biggest drugmaker announced the disposal of $10 billion (8.6 billion pounds) worth of assets to cut debt in May last year, and also said it was selling TachoSil, a surgical patch for bleeding control, to Johnson & Johnson’s Ethicon for $400 million.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.